The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

Specific inhibitors of hepatitis C virus (HCV) replication that target the NS3/4A protease (e.g., VX-950) or the NS5B polymerase (e.g., R1479/R1626, PSI-6130/R7128, NM107/NM283, and HCV-796) have advanced into clinical development. Treatment of patients with VX-950 or HCV-796 rapidly selected for dr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: McCown, Matthew F., Rajyaguru, Sonal, Le Pogam, Sophie, Ali, Samir, Jiang, Wen-Rong, Kang, Hyunsoon, Symons, Julian, Cammack, Nick, Najera, Isabel
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology (ASM) 2008
Schlagworte:
Antiviral Agents
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2346640/
https://ncbi.nlm.nih.gov/pubmed/18285474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01317-07
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge